Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Change in Accured Expenses: 2020-2025

Historic Change in Accured Expenses for Lyell Immunopharma (LYEL) over the last 5 years, with Sep 2025 value amounting to $572,000.

  • Lyell Immunopharma's Change in Accured Expenses fell 81.51% to $572,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.8 million, marking a year-over-year decrease of 695.39%. This contributed to the annual value of -$1.2 million for FY2024, which is 73.85% down from last year.
  • Latest data reveals that Lyell Immunopharma reported Change in Accured Expenses of $572,000 as of Q3 2025, which was up 117.18% from -$3.3 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Change in Accured Expenses ranged from a high of $5.4 million in Q4 2022 and a low of -$9.8 million during Q1 2025.
  • For the 3-year period, Lyell Immunopharma's Change in Accured Expenses averaged around -$1.3 million, with its median value being -$1.3 million (2024).
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first spiked by 396.08% in 2023, then slumped by 745.35% in 2025.
  • Lyell Immunopharma's Change in Accured Expenses (Quarterly) stood at $4.2 million in 2021, then grew by 27.41% to $5.4 million in 2022, then crashed by 132.37% to -$1.7 million in 2023, then rose by 27.89% to -$1.3 million in 2024, then tumbled by 81.51% to $572,000 in 2025.
  • Its Change in Accured Expenses stands at $572,000 for Q3 2025, versus -$3.3 million for Q2 2025 and -$9.8 million for Q1 2025.